drugset / Trial / NCT04362007
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Phase 1 (dose-escalation part): Investigate the tolerability and safety of ASTX660 in patients with r/r PTCL and r/r CTCL and determine the recommended dose (RD) for the Phase 2. Phase 1 (ATLL expansion part): Evaluate the safety of ASTX660 at RD in patients with r/r ATLL. Phase 2 : Evaluate the efficacy of ASTX660 at RD in patients with r/r PTCL.
Timeline
- Start
- 2020-07-14
- Primary completion
- 2024-11-30
- Completion
- 2024-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASTX660 | Small molecule | — | — |